Tagged AGE


Son of a.. Almost Missed This Little Spin-off!

ALAMEDA, Calif.–(BUSINESS WIRE)–Jun. 8, 2018– BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, announced that a draft registration statement on Form 10 was submitted to the U.S. Securities and Exchange Commission (the “SEC”). The draft registration statement relates to the proposed distribution of some or all of BioTime’s shares of AgeX Therapeutics, Inc. (“AgeX”) common stock,…